Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System

Michele Fusaroli,Stefano Polizzi,Luca Menestrina,Valentina Giunchi,Luca Pellegrini,Emanuel Raschi,Daniel Weintraub,Maurizio Recanatini,Gastone Castellani,Fabrizio De Ponti,Elisabetta Poluzzi
DOI: https://doi.org/10.1007/s40264-024-01471-z
2024-08-19
Drug Safety
Abstract:Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice.
pharmacology & pharmacy,public, environmental & occupational health,toxicology
What problem does this paper attempt to address?